Colin Walsh
Angel Investor @ Goldman Sachs Alternatives
San Francisco, United States
Colin Walsh is a Series B investor at Goldman Sachs Alternatives in San Francisco focused on Biotechnology and Health Care. Colin Walsh is based out of Alachua, Florida and is the Managing Director of Life Sciences of Goldman Sachs Alternatives and Board of Director of Beacon Therapeutics. Colin previously worked at Qiming Venture Partners USA as a Partner. Colin Walsh attended the University of Massachusetts, Amherst.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 54%
Last updated:
For AI agents: llms.txt
Industries Colin Walsh invests in
Stages Colin Walsh invests in
Countries Colin Walsh invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 8 (62%)
- Health Care 7 (54%)
- Medical 5 (38%)
- Life Science 3 (23%)
- Therapeutics 3 (23%)
Stage
- Series B 4 (31%)
- Series A 3 (23%)
- Series C 2 (15%)
- Funding Round 2 (15%)
Country
- United States 7 (54%)
- United Kingdom 2 (15%)
- Canada 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions. | $200M / Series A / Jan 09, 2026 | ||
Attovia Therapeutics
|
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated. | $90M / Series C / Apr 15, 2025 | |
| Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses. Vicebio is a biopharmaceutical business that creates innovative vaccinations to prevent potentially fatal respiratory viral infections. | $100M / Series B / Sep 23, 2024 | ||
|
Attovia Therapeutics
|
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated. | $105M / Series B / May 09, 2024 | |
| Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs. | $142M / Series B / Apr 20, 2023 | ||
| Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins. | $81M / Series A / Dec 06, 2022 | ||
| Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases. The Company’s wholly owned and proprietary U1 Adaptor technology promotes non-genotoxic and long-lasting silencing of disease-causing genes in difficult to target tissues (i.e., outside of the liver and CNS). | $75M / Series A / Jan 19, 2022 | ||
| Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health. | $17M / Series B / Oct 20, 2016 | ||
| Pulse Therapeutics is a growing medical technology company headquartered in St. Louis, Mo. The medical developer is advancing the fight against stroke, heart disease, and other conditions with its high-level treatment solutions, which utilize the latest biomedical technology and processes.Pulse’s signature offering, the MED System, was designedto harness magnet-based technology to rapidly dissolve blood clots faster than current modalities. This faster rate of delivery of FDA-approved clot-busting medication could dramatically reduce the number of lives lost each year to stroke, heart disease, and other diseases.This pioneering medical development company was founded by leading physicists Francis “Duke” Creighton and Rogers Ritter. Dr. Creighton, who also serves as Pulse’s chief technical officer, has 20-plus years of expertise in the medical technology industry, specializing in the stroke and cardiovascular sectors. He responsible for 30 patents and is a technology reviewer for the National Cancer Institute, National Science Foundation, and National Institutes of Health.The ground-breaking medical solutions of Pulse Therapeutics continues to attract investors and garner media coverage. | $10M / Jan 27, 2016 | ||
| Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness. | $75M / Series C | ||
| See all 13 investments → | |||
Co-Investors
Goldman Sachs Alternatives specializes in investment strategies that encompass private equity, private credit, real estate, and infrastructure. The firm leverages its extensive network and expertise to identify and manage alternative asset opportunities. By integrating sustainability and inclusion into its investment approach, Goldman Sachs aims togenerate positive impacts alongside financial returns.
Goldman Sachs Alternatives Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ben Fife
Vice President - GS Growth
|
|||
Gabriel Mollerberg
Managing Director
|
|||
Teresa Mattamouros
Managing Director, Asset & Wealth Management (Infrastructure Fund)
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Colin Walsh invest in?
Colin Walsh invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Colin Walsh?
Public channels for Colin Walsh include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Colin Walsh last invest?
The most recent investment recorded for Colin Walsh closed in Jan 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
